Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature.

Literature DB >> 23135613

Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature.

G M Guidelli¹, A Fioravanti, P Rubegni, L Feci.

Abstract

Rituximab is a human/murine monoclonal antibody targeting the CD20 antigen on B-lymphocytes surface. Although it has been licensed for treatment of non-Hodgkin's lymphoma, nowadays it is also a novel therapy for autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. Despite the increasing evidence regarding the safety and efficacy of rituximab in these conditions, many cutaneous adverse events have been reported. Here, we describe the case of a 69-year-old patient, affected by rheumatoid arthritis, who developed psoriatic lesions on her trunk and arms, three months after the second course of rituximab. Similar cases appearing in the literature will also be briefly mentioned.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 23135613 DOI： 10.1007/s00296-012-2581-3

Source DB: PubMed Journal: Rheumatol Int ISSN： 0172-8172 Impact factor: 2.631

15 in total

1. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

Authors: U Winkler; M Jensen; O Manzke; H Schulz; V Diehl; A Engert
Journal: Blood Date: 1999-10-01 Impact factor: 22.113

2. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab).

Authors: C A D'Arcy; M Mannik
Journal: Arthritis Rheum Date: 2001-07

3. Development of psoriasis after B cell depletion with rituximab.

Authors: Shouvik Dass; Edward M Vital; Paul Emery
Journal: Arthritis Rheum Date: 2007-08

Review 4. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.

Authors: Young Ho Lee; Sang-Cheol Bae; Gwan Gyu Song
Journal: Rheumatol Int Date: 2010-05-16 Impact factor: 2.631

5. Complement activation plays a key role in the side-effects of rituximab treatment.

Authors: L E van der Kolk; A J Grillo-López; J W Baars; C E Hack; M H van Oers
Journal: Br J Haematol Date: 2001-12 Impact factor: 6.998

6. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Authors: Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek Szczepanski; Arthur Kavanaugh; Artur J Racewicz; Ronald F van Vollenhoven; Nicole F Li; Sunil Agarwal; Eva W Hessey; Timothy M Shaw
Journal: Arthritis Rheum Date: 2006-05

7. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab.

Authors: T E Markatseli; E S Kaltsonoudis; P V Voulgari; A Zioga; A A Drosos
Journal: Clin Exp Rheumatol Date: 2009 Nov-Dec Impact factor: 4.473

8. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry.

Authors: Laure Thomas; Florence Canoui-Poitrine; Jacques-Eric Gottenberg; Andra Economu-Dubosc; Fatiha Medkour; Xavier Chevalier; Sylvie Bastuji-Garin; Hervé Le Louët; Valérie Farrenq; Pascal Claudepierre
Journal: J Rheumatol Date: 2012-04-15 Impact factor: 4.666

9. Stevens-Johnson syndrome after treatment with rituximab.

Authors: S Lowndes; A Darby; G Mead; A Lister
Journal: Ann Oncol Date: 2002-12 Impact factor: 32.976

Review 10. Pathogenic mechanisms shared between psoriasis and cardiovascular disease.

Authors: Ramin Ghazizadeh; Hajime Shimizu; Mamiko Tosa; Mohammad Ghazizadeh
Journal: Int J Med Sci Date: 2010-08-19 Impact factor: 3.738

11 in total

Review 1. A comprehensive review of rituximab therapy in rheumatoid arthritis patients.

Authors: Soheil Tavakolpour; Samira Alesaeidi; Mohammad Darvishi; Mojtaba GhasemiAdl; Sahar Darabi-Monadi; Meisam Akhlaghdoust; Somayeh Elikaei Behjati; Arash Jafarieh
Journal: Clin Rheumatol Date: 2019-08-01 Impact factor: 2.980

Review 2. Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.

Authors: Maria Vastarella; Gabriella Fabbrocini; Vincent Sibaud
Journal: Drug Saf Date: 2020-05 Impact factor: 5.606

3. IL-10+ Innate-like B Cells Are Part of the Skin Immune System and Require α4β1 Integrin To Migrate between the Peritoneum and Inflamed Skin.

Authors: Skye A Geherin; Daniela Gómez; Raisa A Glabman; Gordon Ruthel; Alf Hamann; Gudrun F Debes
Journal: J Immunol Date: 2016-02-05 Impact factor: 5.422

4. A Case of Psoriasis Accompanied by Systemic Lupus Erythematosus.

Authors: Eun Jee Kim; Hyun Sun Park; Hyun-Sun Yoon; Soyun Cho
Journal: Ann Dermatol Date: 2015-05-29 Impact factor: 1.444

5. Rituximab Treatment in a Patient with Active Graves' Orbitopathy and Psoriasis.

Authors: Tülay Şimşek; Nilgün Yıldırım; Belgin Efe; Nur Kebapçı
Journal: Turk J Ophthalmol Date: 2017-01-17

Review 6. Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases-Implications for Therapeutic Approaches.

Authors: Tanja Fetter; Dennis Niebel; Christine Braegelmann; Joerg Wenzel
Journal: Cells Date: 2020-12-07 Impact factor: 6.600